Astrazeneca Plc

Astrazeneca (AZN)

Trade Now

Capital at risk Advertisement
Company name:Astrazeneca Plc
Company Description:A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:AZNTrading Currency:GBX
Market Sector:FE10ISIN:GB0009895292
Market Segment:SET1Share Type:DE
WWW Address:http://www.astrazeneca.com/Description:ORD SHS $0.25
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 9,838.00 images.advfn.com/imagesnew/2/gb/down -106.0 [-1.07] 9,845.00 9,847.00 9,955.00 10,000.00 9,789.00 1,787,918
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 152,402.04 1,549.12 -0.61 6.99 212.23 1,408.20 2.16 11,540.00 - 8,091.00

Astrazeneca Key Figures

(at previous day's close)
Market Cap.152,402.04m
Shares In Issue1,549.12m
Prev. Close9,944.00
PE Ratio1,408.20 
Dividend Yield2.16%
EPS - basic6.99p
Dividend PS212.23p
Dividend Cover- 
Cash Flow PS284.64p
Return On Equity (ROE)0.29%
Operating Margin-0.71%
PEG Factor-14.56 
EPS Growth Rate-96.72%
Dividends PS Growth Rate2.50%
Net Debt44,181.28m
Gross Gearing62.71%
Quick Assets16,437.74m
Net Working Capital6,372.78m
Intangibles / Fixed Assets84.27%
Turnover PS1,786.11p
Pre-Tax Profit PS-12.65p
Retained Profit PS-178.72p
Cash PS302.12p
Net Cash PS-776.41p
Net Tangible Asset Value PS *-1,108.46p
Net Asset Value PS1,875.37p
Spread2.00 (0.02%) 

Astrazeneca Balance Sheet

L^AZN:Liabilities+EQL^AZN:Assets

Share Price Performance

Sample Period HighLow
1 week10,046.009,667.00
4 weeks10,624.009,667.00
12 weeks11,540.009,667.00
1 year11,540.008,091.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week9,979.00-141.00-1.419,667.002.309,923.93
4 weeks10,372.00-534.00-5.159,667.002.6710,077.23
12 weeks10,948.00-1,110.00-10.149,667.002.2410,552.37
26 weeks10,242.00-404.00-3.949,399.002.3910,475.24
1 year8,739.001,099.0012.588,091.002.289,698.36
3 years6,979.002,859.0040.975,871.002.388,438.65
5 years5,119.004,719.0092.194,544.502.317,424.88

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio123.72 
PE Ratio1,408.20 
Tobin's Q Ratio 1.77 
Tobin's Q Ratio (excl. intangibles)4.00 
Dividend Yield2.16%
Market-to-Book Ratio5.25 
Price-to-Pre-Tax Profit PS-777.72 
Price-to-Retained Profit PS-55.05 
Price-to-Cash Flow PS34.56 
Price-to-Sales PS5.51 
Price-to-Net Tangible Asset Value PS-8.88 
Price-to-Cash PS32.56 
Net Working Capital PS411.38 
Price Pct to Working Capital PS23.91%
Earnings Yield0.07%
Average PE248.96 
Years in average5 
PE to PE average565.64%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio52.53%
Debt-to-Equity Ratio1.11 
Debt-to-Equity Ratio (excl. Intgbl)-1.87 
Debt-to-Equity Market Value0.21 
Net Gearing56.71%
Net Gearing (excl. Intangibles)139.35%
Gross Gearing62.71%
Gross Gearing (excl. Intangibles)154.12%
Gearing Under 1 Year21.44%
Gearing Under 1 Year (excl. Intgbl)52.70%
Assets/Equity2.68 
Cash/Equity16.11 
(Liquidity Ratios)
Net Working Capital to Total Assets8.18%
Current Ratio1.38 
Quick Ratio (Acid Test)0.98 
Liquidity Ratio0.28 
Cash & Equiv/Current Assets20.28%
(Solvency Ratios)
Enterprise Value179,889.72m
CFO/Sales0.16 
CFO/Attributable Profit53.24 
CFO/Assets0.06 
CFO/Debt0.09 
Total Debt/Equity Market Value0.32 
Total Debt/Sales1.77 
Total Debt/Pre-Tax Profit-249.34 
Total Debt48,861.40m
Total Debt/Net Current Assets7.67%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs10 
Beta (60-Mnth)Beta (36-Mnth)
-0.61410.9649

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-0.32%
Return On Assets (ROA)0.10%
Net Profit Margin0.30%
Assets Turnover0.32 
Return On Equity (ROE)0.29%
Return On Investment (ROI)0.13%
Dividend Payout Ratio3,587.50%
Plowback Ratio-3,487.50%
Growth from Plowback Ratio-10.52%
Net Income Of Revenues-10.01%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.01 
Fixed Assets Turnover0.47 
Current Assets Turnover1.01 
Net Working Capital Turnover 
Inventory Turnover4.25 
(Other Operating Ratios)
Total Assets-to-Sales3.11 
Debtors-to-Sales49.59%
Debt Collection Period181.02Days

Astrazeneca Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
29 Jul 2022InterimUSX93.0031/12/202131/12/202211/08/202212/08/202212/09/2022-
10 Feb 2022InterimUSX197.0031/12/202031/12/202124/02/202225/02/202228/03/2022287.00
29 Jul 2021InterimUSX90.0031/12/202031/12/202112/08/202113/08/202113/09/2021-
16 Feb 2021InterimUSX190.0031/12/201931/12/202025/02/202126/02/202129/03/2021280.00
30 Jul 2020InterimUSX90.0031/12/201931/12/202013/08/202014/08/202014/09/2020-
14 Feb 2020InterimUSX190.0031/12/201831/12/201927/02/202028/02/202030/03/2020280.00
25 Jul 2019InterimUSX90.0031/12/201831/12/201908/08/201909/08/201909/09/2019-
14 Feb 2019FinalUSX190.0031/12/201731/12/201828/02/201901/03/201927/03/2019280.00
26 Jul 2018InterimUSX90.0031/12/201731/12/201809/08/201810/08/201810/09/2018-
02 Feb 2018FinalUSX190.0031/12/201631/12/201715/02/201816/02/201819/03/2018280.00
27 Jul 2017InterimUSX90.0031/12/201631/12/201710/08/201711/08/201711/09/2017-
02 Feb 2017FinalUSX190.0031/12/201531/12/201616/02/201717/02/201720/03/2017280.00
28 Jul 2016InterimUSX90.0031/12/201531/12/201611/08/201612/08/201612/09/2016-
04 Feb 2016FinalUSX190.0031/12/201431/12/201518/02/201619/02/201621/03/2016280.00
30 Jul 2015InterimUSX90.0031/12/201431/12/201513/08/201514/08/201514/09/2015-
05 Feb 2015FinalUSX190.0031/12/201331/12/201419/02/201520/02/201523/03/2015280.00
31 Jul 2014InterimUSX90.0031/12/201331/12/201413/08/201415/08/201415/09/2014-
06 Feb 2014FinalUSX190.0031/12/201231/12/201319/02/201421/02/201424/03/2014280.00
01 Aug 2013InterimUSX90.0031/12/201231/12/201314/08/201316/08/201316/09/2013-
31 Jan 2013FinalUSX190.0031/12/201131/12/201213/02/201315/02/201318/03/2013280.00
26 Jul 2012InterimUSX90.0031/12/201131/12/201208/08/201210/08/201210/09/2012-
02 Feb 2012FinalUSX195.0031/12/201031/12/201115/02/201217/02/201219/03/2012280.00
28 Jul 2011InterimUSX85.0031/12/201031/12/201103/08/201105/08/201112/09/2011-
27 Jan 2011FinalUSX185.0031/12/200931/12/201002/02/201104/02/201114/03/2011255.00
29 Jul 2010InterimUSX70.0031/12/200931/12/201002/08/201004/08/201013/09/2010-
28 Jan 2010FinalUSX171.0031/12/200831/12/200903/02/201005/02/201015/03/2010230.00
30 Jul 2009InterimUSX59.0030/12/200830/06/200905/08/200907/08/200914/09/2009-
29 Jan 2009FinalUSX150.0031/12/200731/12/200804/02/200906/02/200916/03/2009205.00
31 Jul 2008InterimUSX55.0030/12/200730/06/200808/08/200806/08/200815/09/2008-
31 Jan 2008FinalUSX135.0031/12/200631/12/200706/02/200808/02/200817/03/2008187.00
26 Jul 2007InterimUSX52.0030/06/200630/06/200708/08/200710/08/200717/09/2007-
01 Feb 2007FinalUSX123.0031/12/200531/12/200607/02/200709/02/200719/03/2007172.00
27 Jul 2006InterimUSX49.0030/12/200530/06/200609/08/200611/08/200618/09/2006-
01 Feb 2006FinalUSX92.0031/12/200431/12/200508/02/200610/02/200620/03/2006130.00
29 Jul 2005InterimUSX38.0030/12/200430/06/200510/08/200512/08/200519/09/2005-
27 Jan 2005FinalUSX64.5031/12/200331/12/200409/02/200511/02/200521/03/200594.00
22 Jul 2004InterimUSX29.5030/12/200330/06/200411/08/200413/08/200420/09/2004-
29 Jan 2004FinalUSX54.0031/12/200231/12/200318/02/200420/02/200406/04/200479.50
24 Jul 2003InterimUSX25.5030/12/200230/06/200320/08/200322/08/200306/10/2003-
30 Jan 2003FinalUSX47.0031/12/200131/12/200219/02/200321/02/200307/04/200370.00
25 Jul 2002InterimUSX23.0030/12/200130/06/200221/08/200223/08/200207/10/2002-
31 Jan 2002FinalUSX47.0031/12/200031/12/200120/02/200222/02/200208/04/200270.00
26 Jul 2001InterimUSX23.0030/12/200030/06/200122/08/200124/08/200105/10/2001-
08 Feb 2001FinalUSX47.0031/12/199931/12/200021/02/200123/02/200109/04/200170.00
01 Aug 2000InterimUSX23.0030/12/199930/06/200004/09/200008/09/200023/10/2000-
24 Feb 2000FinalUSX47.0031/12/199831/12/199906/03/200010/03/200017/04/200070.00
03 Aug 1999InterimUSX23.0030/12/199830/06/199906/09/199910/09/199925/10/1999-

Astrazeneca Fundamentals

 31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)31 Dec 2021 (USD)
turnover22,090.00100.00%24,384.00100.00%26,617.00100.00%37,417.00100.00%m
pre tax profit1,993.009.02%1,548.006.35%3,916.0014.71%-265.00-0.71%m
attributable profit2,155.009.76%1,335.005.47%3,196.0012.01%112.000.30%m
retained profit-1,329.00-6.02%-2,257.00-9.26%-376.00-1.41%-3,744.00-10.01%m
eps - basic170.00 103.00 244.00 8.00 
eps - diluted170.00 103.00 244.00 8.00 
dividends per share280.00 280.00 280.00 287.00 

Astrazeneca Balance Sheet

 31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)31 Dec 2021 (USD)
L^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:Assets
 31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)31 Dec 2021 (USD)
ASSETS
fixed assets fixed assets7,421.0012.24%7,688.0012.53%8,251.0012.36%10,171.009.65%m
intangibles intangibles33,666.0055.51%33,148.0054.01%33,458.0050.14%62,489.0059.31%m
fixed investments fixed investments2,186.003.60%2,405.003.92%1,620.002.43%1,491.001.42%m
current assets - other current assets - other--%70.000.11%--%--%m
stocks stocks2,890.004.76%3,193.005.20%4,024.006.03%8,983.008.53%m
debtors debtors9,657.0015.92%9,504.0015.48%11,544.0017.30%15,900.0015.09%m
cash & securities cash & securities4,831.007.97%5,369.008.75%7,832.0011.74%6,329.006.01%m
TOTAL60,651.00100%61,377.00100%66,729.00100%105,363.00100%m
LIABILITIES
creditors - short creditors - short16,292.0026.86%18,117.0029.52%20,307.0030.43%22,594.0021.44%m
creditors - long creditors - long30,315.0049.98%28,664.0046.70%30,784.0046.13%43,482.0041.27%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL46,607.0076.84%46,781.0076.22%51,091.0076.56%66,076.0062.71%m
EQUITY
ord cap, reserves ord cap, reserves12,468.0020.56%13,127.0021.39%15,622.0023.41%39,268.0037.27%m
prefs, minorities prefs, minorities1,576.002.60%1,469.002.39%16.000.02%19.000.02%m
TOTAL14,044.0023.16%14,596.0023.78%15,638.0023.44%39,287.0037.29%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Astrazeneca Cash Flow Statement

31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)31 Dec 2021 (USD)
Operating CF2,618.002,969.004,799.005,963.00m
Pre-Financing CF3,581.002,312.004,514.00-5,095.00m
Retained CF1,537.00547.002,311.00-1,446.00m

Astrazeneca Brokers

NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Nyenburgh Holding B.V.Market Maker(MME)Broker/DealerNYBBNYENNL2B
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221006 22:33:23